Original articles
1. Ota H, Mahmoudi M, Torguson R, Satler LF, Suddath WO, Pichard AD, Waksman R (2015). Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis. Cardiovasc Revasc Med, 16, 328-330
2. Tian W, Mahmoudi M, Lhermusier T, Pendyala LK, Kiramijyan S, Saar M, Ota H, Chen F, Torguson R, Suddath WO, Satler LF, Pichard AD, Waksman R (2015). Clinical outcomes of first- and second-generation drug-eluting stents in patients undergoing rotational atherectomy for heavily calcified coronary lesions. Cardiovasc Revasc Med, 16, 147-150
3. Ota H, Mahmoudi M, Kitabata H, Torguson R, Chen F, Satler LF, Suddath WO, Pichard AD, Waksman R (2015). Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis. Cardiovasc Revasc Med, 16, 84-89
4. Williams TM, Waksman R, De Silva K, Jaques A, Mahmoudi M (2015). Ischemic preconditioning-an unfulfilled promise. Cardiovasc Revasc Med, 16, 101-108
5. De Silva K, Mahmoudi M (2015). Isolated coronary artery aneurysms presenting with ST-elevation myocardial infarction – a case of when less is more. Coron Artery Dis, 26, 88-90
6. Zeb M, Mahmoudi M, Garty F, Bannister C, Reddiar R, Nicholas Z, Crouch R, Heyworth J, Curzen N (2014). Detection of regional myocardial ischemia by a novel 80-electrode body surface Delta map in patients presenting to the emergency department with cardiac sounding chest pain. Eur J Emerg Med, 21, 89-97
7. Delhaye C, Kpogbemabou N, Modine T, Lemesle G, Staels B, Mahmoudi M, Tailleux A, Luc G, Bauters C, Lablanche J (2013). Long-term prognostic value of pre-procedural adiponectin levels in patients undergoing percutaneous coronary intervention. Inter J Cardiol, 168, 4921-4924
8. Mahmoudi M, Delhaye C, Waksman R (2012). Hypothermia therapy: Neurological and Cardiac Benefits. J Am Coll Cardiol, 17, 197-210
9. Mahmoudi M, Hauville C, Gaglia MA, Sardi G, Torguson R, Xue Z, Satler LF, Suddath WO, Pichard AD, Waksman R (2012). The impact of intra-aortic balloon counter-pulsation on in-hospital mortality in patients presenting with anterior ST-elevation myocardial infarction without cardiogenic shock. Cardiovasc Revasc Med, 13, 328-330
10. Mahmoudi M, Harden S, Abid N, Peebles C, Nicholas Z, Jones T, McKenzie D, Curzen N (2012). Toponin positive chest pain with unobstructed coronary arteries: Definitive differential diagnosis using cardiac MRI. Br J Radiol, 85, e461-466
11. Mahmoudi M, Waksman R (2012). Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary intervention. Minerva Cardioangiol, 60, 95-100
12. Maluenda G, Ben-Dor I, Gaglia MA, Wakabayashi K, Mahmoudi M, Sardi G, Laynez-Carnicero A, Torguson R, Xue Z, Margulies AD, Suddath WO, Kent KM, Bernardo NL, Satler LF, Pichard AD, Waksman R (2012). Clinical outcomes and treatment after drug-eluting stent failure: the absence of traditional risk factors for in-stent re-stenosis. Circ Cardiovasc Interv, 5, 12-19
13. Ben-Dor I, Maluenda G, Mahmoudi M, Torguson R, Xue Z, Bernardo NL, Lindsay J, Satler LF, Pichard AD, Waksman R (2012). A novel, minimally invasive access technique versus standard 18-gauge needle set for femoral access. Catheter Cardiovasc Interv, 79, 1180-1185
14. Mahmoudi M, Waksman R (2012). Bifurcation stenting: The current state of play. Cardiovasc Revasc Med, 13, 51-57
15. Wakabayashi K, Pakala R, Mahmoudi M, Watanabe T, Mori H, Iso Y, Suzuki H (2012). Novel technologies and future perspectives of drug eluting stents. Translational Med, S:7
16. Mahmoudi M, Hill P, Xue Z, Torguson R, Ali G, Boyce SW, Baffi AS, Corso PJ, Waksman R (2011). Patients with severe asymptomatic carotid artery stenosis do not have a higher risk of stroke and mortality following coronary artery bypass surgery. Stroke, 42, 2801-2805
17. Mahmoudi M, Delhaye C, Wakabayashi K, Ben-Dor I, Gonzalez M, Maluenda G, Gaglia M, Torguson R, Xue Z, Satler L, Suddath W, Kent K, Pichard A, Waksman R (2011). Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents. Am J Cardiol, 107, 1757-1762
18. Mahmoudi M, Syed A, Ben-Dor I, Gonzalez M, Maluenda G, Gaglia M, Sardi G, Wakabayashi K, Torguson R, Xue Z, Satler L, Suddath W, Pichard A, Waksman R (2011). Safety and efficacy of clopidogrel reloading in patients on chronic clopidogrel therapy who present with an acute coronary syndrome and undergo percutaneous coronary intervention. Am J Cardiol, 107, 1779-1782
19. Mahmoudi M, Delhaye C, Wakabayashi K, Torguson R, Xue Z, Satler L, Suddath W, Kent K, Pichard A, Waksman R (2011). Integrelin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Journal of Interv Cardiol, 24, 351-356
20. Mahmoudi M, Delhaye C, Waksman R (2011). Safety and efficacy of drug-eluting and bare-metal stents in acute coronary syndrome. Cardiovasc Revasc Med, 12, 385-390
21. Gaglia MA JR, Torguson R, Pakala R, Xue Z, Sardi G, Mahmoudi M, Suddath W, Kent K, Satler LF, Pichard A, Waksman R (2011). Relation of body mass index on-treatment (clopidogrel+aspirin) platelet reactivity. Am J Cardiol, 108, 766-771
22. Belle L, Mahmoudi M, Delhaye C, Ben-Dor I, Maluenda G, Gaglia M, Torguson R, Satler LF, Pichard A, Waksman R (2011). Do Patients with drug-eluting stent thrombosis have a similar prognosis to patients presenting with ST-elevation myocardial infarction of de novo lesions? Journal of Interv Cardiol, 24, 320-325
23. Wakabayashi K, Delhaye C, Mahmoudi M, Belle L, Ben-Dor I, Gaglia MA, Satler LF, Kent KM, Pichard AD, Lindsay J, Waksman R (2011). Impact of drug-eluting stent type on periprocedural myocardial necrosis. Eurointervention, 7, 136-142
24. Wakabayashi K, Romaguera R, Laynez-Carnicero A, Maluenda G, Ben-Dor I, Sardi G, Mahmoudi M, Gonzalez MA, Delhaye C, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Lindsay J, Waksman R (2011). Impact of smoking on acute phase outcomes of myocardial infarction. Coron Artery Dis, 22, 217-222
25. Ben-Dor I, Mahmoudi M, Pichard AD, Satler LF, Waksman R (2011). Optical coherence tomography – A new imaging modality for plaque characterisation and stent implantation. Journal of Interv Cardiol, 24, 184-192
26. Mahmoudi M, Syed A, Waksman R (2011). The role of percutaneous circulatory assist devices in acute myocardial infarction and high-risk percutaneous coronary intervention in the 21st century. Cardiovasc Revasc Med, 12, 237-242
27. Gaglia MA Jr, Torguson R, Xue Z, Gonzalez MA, Ben-Dor I, Maluenda G, Mahmoudi M, Sardi G, Wakabayashi K, Kaneshige K, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R (2010). Effect of insurance type on adverse cardiac events after percutaneous coronary intervention. Am J Cardiol, 107, 675-680
28. Gaglia MA Jr, Torguson R, Gonzalez MA, Ben-Dor I, Maluenda G, Collins SD, Syed AI, Delhaye C, Wakabayashi K, Belle L, Mahmoudi M, Hanna N, Xue Z, Kaneshige K, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R (2010). Correlates and consequences of gastrointestinal bleeding complicating percutaneous coronary intervention. Am J Cardiol, 106, 1069-1074
29. Mercer J, Cheng K, Figg N, Gorenne I, Mahmoudi M, Griffin J, Vidal-Puig A, Logan A, Murphy MP, and Bennett MR (2010). DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res, 107, 1021-1031
30. Mahmoudi M, Waksman R (2010). Drug-eluting stents for acute coronary syndromes: Should the labelling be expanded. Interv Cardiol, 2, 249-252
31. Mahmoudi M, Gorenne I, Mercer J, Figg N, Littlewood T, and Bennett MR (2008). Statins utilize a novel NBS-dependent pathway to accelerate DNA repair in vascular smooth muscle cells. Circ Res, 103, 712-725
32. Mahmoudi M, Curzen NP, and Gallagher PJ (2007). Angiogenesis: the role of inflammation and infection. Histopathology, 50, 535-546
33. Mercer J, Mahmoudi M, and Bennett MR (2007). DNA damage, p53, apoptosis and vascular disease. Mut Res, 621, 75-86
34. Mahmoudi M, Mercer J, and Bennett MR (2006). DNA damage and repair in atherosclerosis. Cardiovascular Research, 71, 259-268
35. Mahmoudi M, McDonagh S, Poole-Wilson S, and Dubrey SW (2003). Obstacles to the initiation of beta-blockers for heart failure in specialized clinic within a district general hospital. Heart, 89, 442-444
36. Meyer T, Nelstrop AE, Mahmoudi M, and Rustin GJS (2001). Weekly cisplatin and oral etoposide as treatment for relapsed ovarian cancer. Ann Oncol, 12, 1-5
37. Rustin GJS, Van Hippelstein M, Nelstrop AE, Mahmoudi M, and Meyer T (2001). Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol, 19, 4054-4057